Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2024-09-25 AGM Information
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Shareholders meeting
AGM Information Classification · 100% confidence The document is titled 'Proceedings of the 33rd Annual General Meeting (AGM) of the Company' and contains a detailed summary of the AGM held on September 25, 2024. It includes information about the meeting's attendees, the agenda items discussed, resolutions passed, and voting procedures. The document does not contain full financial statements or detailed financial analysis but rather a summary of the meeting proceedings. It explicitly states it is a summary of AGM proceedings, which aligns with the category AGM Information (AGM-R). The document length (6289 characters) supports it being a detailed summary rather than a brief announcement or a full annual report. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-09-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges regarding an order received from the Reserve Bank of India (RBI) related to a regulatory compliance matter involving ESOP approvals and R&D expenditure conditions. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to continuous disclosures by listed entities. The document details the nature of the order, the violation, and the financial impact (a compounding fee of Rs. 1.51 Crs). The content is an announcement of a regulatory event and compliance disclosure rather than a financial report, earnings release, or management discussion. The document length is 4281 characters, which is relatively short and consistent with a regulatory disclosure notice. There is no financial statement or detailed financial analysis present. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-09-17 English
Press Release
Capital/Financing Update Classification · 85% confidence The document is a press release announcing the USFDA approval of a pharmaceutical product (Fluoxetine Tabs 60 mg) by Strides Pharma Science Limited. It is addressed to stock exchanges and includes contact information for investor relations. The document is relatively short (3942 characters) and does not contain any financial data, detailed financial performance, or regulatory filings. It is an announcement of a corporate event (product approval) rather than a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) as it relates to a significant corporate development impacting the company's product portfolio and market position, which can influence capital markets and investor perception.
2024-09-16 English
Updates
M&A Activity Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the update on the Scheme of Amalgamation of Strides Alathur Private Limited into Strides Pharma Science Limited. It references the approval by the National Company Law Tribunal (NCLT) and the filing of certified copies of the order with the Registrar of Companies. The document announces the effective date of the scheme and changes in authorized share capital. It is a formal announcement of a corporate restructuring event, specifically an amalgamation, and not a full report or detailed financial statement. The document length is short (1704 characters) and it serves as an update on a merger-related event rather than a merger proxy statement or detailed merger filing. Therefore, the most appropriate classification is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2024-09-12 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the approval from equity shareholders and secured creditors for the creation of OneSource, a specialty pharma CDMO. It mentions approvals from shareholders and creditors, meetings under the National Company Law Tribunal, and next steps involving final approval and listing. The document is an announcement of a corporate event related to shareholder and creditor approvals, not a detailed financial report, earnings release, or management discussion. It is not a voting results declaration since it does not provide official vote counts or detailed voting outcomes, but rather a general announcement of approvals. It is also not a merger or acquisition filing, but rather a strategic corporate restructuring announcement. Given the nature of the document as a press release informing the market and stakeholders about a significant corporate development and approvals, the best fitting category is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 4657 characters, which is consistent with a press release rather than a full report. Confidence is high due to clear references to shareholder and creditor approvals and strategic corporate restructuring.
2024-09-11 English
Shareholders meeting
Regulatory Filings
2024-09-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.